MERLINTRADER DAILY BRIEFING
Tuesday Briefing: Monday’s Semiconductor Drawdown, Two FDA Rulings, and the Nvidia Clock
Monday’s official U.S. close read against the primary filings and agency documents that produced it, with the week’s fixed regulatory and macro dates laid out in order.
$SPYMonday close: 763.47 (-0.29%)
Executive Summary
Monday was a composition story, not a macro story. The Dow closed higher and the Nasdaq Composite closed lower on the same session, because semiconductors gave back ground while banks, payments and utilities absorbed capital. No single data release explains the split.
The index picture
The S&P 500 settled at 7,652.86, down 0.28%. The Nasdaq Composite lost 0.76% to 25,980.19. The Dow Jones Industrial Average added 140.15 points, or 0.26%, to 53,417.16. Among the index ETFs, $SPY closed 763.47 (-0.29%), $QQQ 706.32 (-1.00%), $DIA 533.65 (+0.27%) and $IWM 297.97 (-0.66%).
The single-name picture
Two FDA actions repriced small-cap biotech inside one session: a three-month extension for Capricor and a clinical hold for Regenxbio. Both were disclosed through company releases and SEC filings dated August 24, so both can be read from primary documents rather than inferred from price.
1. Monday Market Snapshot
| Instrument | Aug 24 close | Day | Read-through |
|---|---|---|---|
| $SPY | 763.47 | -0.29% | Marginal decline; direction decided by sector weight. |
| $QQQ | 706.32 | -1.00% | Semiconductor exposure carried the drag. |
| $DIA | 533.65 | +0.27% | Only major index ETF to close higher. |
| $IWM | 297.97 | -0.66% | Small caps followed the risk tape lower. |
| $SMH | 546.80 | -2.43% | Heaviest large-group decline of the session. |
| $XLF | 58.22 | +1.29% | Financials provided the offset. |
| $XLU | 43.22 | +1.05% | Defensive bid alongside falling yields. |
| $XBI | 164.17 | -0.94% | Biotech slipped despite two large single-name moves. |
| $TLT | 82.56 | +0.62% | Long duration rose as the 10-year eased. |
| $GLD | 426.69 | +0.79% | Spot gold at its highest since mid-May. |
The sector spread is the number that matters. $XLK closed 180.05, down 1.78%, the weakest of the sector funds, while $XLF and $XLU finished higher. When the leadership rotates from technology into financials and utilities in a single session without a macro catalyst, positioning ahead of a known event is the more economical explanation than a change in the macro regime.
2. The Semiconductor Drawdown and What Offset It
Where the damage was
$MU closed 910.43, down 5.83% on roughly 30.0 million shares, the largest decline among the mega-cap semiconductor names. $AMD ended 456.74 (-3.49%), $AVGO 358.76 (-2.63%) and $MRVL 229.29 (-3.27%). $NVDA closed 208.48, down 2.91%, on 135.2 million shares, the heaviest volume on the board. $SOXX finished 506.18 (-2.67%).
Where the money went
$V closed 382.41 (+3.06%) and $MA 599.86 (+3.31%), both at record levels. $XLF rose 1.29% and $XLU 1.05%. Hardware did not participate in the rotation: $DELL closed 433.19 (-2.01%) and $HPQ 28.58 (-3.80%), both with their own reporting dates ahead.
The distinction worth holding is between a sector that is being sold and a sector that is being de-risked before a scheduled event. Broad, uniform weakness across memory, logic and networking, rather than a single company breaking down, is more consistent with the second. That reading is testable on Wednesday evening, when the reason for the caution either arrives or does not.
3. Capricor: A Three-Month Extension, Not a Decision
What the company disclosed
Capricor announced on August 24 that the FDA has extended the PDUFA target action date for the deramiocel Biologics License Application in Duchenne muscular dystrophy from August 22, 2026 to November 22, 2026. The agency classified the additional Phase 3 HOPE-3 data and analyses submitted after the July 29 advisory committee as a major amendment, which carries a three-month extension of the review clock. The company filed a Form 8-K the same day.
How the tape read it
$CAPR closed 6.80, up 8.11%, on approximately 20.1 million shares. The advance followed a Friday session in which the stock had fallen ahead of the original target date. An extension removes the immediate binary outcome; it does not change the substance of the review, and it does not indicate the direction of the eventual decision.
The July 29 advisory committee voted 3 in favor and 9 against on whether the application demonstrated substantial evidence of effectiveness. That vote is advisory and does not bind the agency, but it is the reason the company submitted additional analyses, and it is the reason those analyses were treated as a major amendment. The new date to carry forward is November 22, 2026.
4. Regenxbio: A Clinical Hold Built on Imaging Findings
The finding
Regenxbio disclosed that the FDA has placed a clinical hold on RGX-121, an investigational gene therapy for mucopolysaccharidosis type II. Enhanced monitoring covering both brain and spine MRI identified asymptomatic findings, either a small nodule or a small cystic mass, in the spine MRIs of five participants in the CAMPSIITE study who received intracisternal or intraventricular RGX-121 approximately three to six years earlier. The company states that all five continue to do well clinically.
The commercial consequence
$RGNX closed 8.06, down 24.86%, on about 5.45 million shares. The company does not expect to resubmit the RGX-121 BLA in the near term. It states that its Duchenne and retinal programs, which use a different capsid and different routes of administration, remain on track, with a Duchenne BLA submission planned for the third quarter of 2026 and wet AMD pivotal topline data expected in the fourth quarter.
Two features of this hold deserve separate treatment. The first is the latency: findings surfaced three to six years after dosing, which is a property of long-duration gene-therapy follow-up rather than of this program alone. The second is the capsid and route argument the company makes for its remaining pipeline. That argument is plausible on its face and it is also the argument every sponsor makes in this position, so the near-term Duchenne submission is the test that either supports it or does not.
5. Rates, Dollar, Oil and Gold
The 10-year Treasury yield eased roughly two basis points to about 4.72%, and $TLT closed 82.56, up 0.62%. The dollar index finished near 98.99, about 0.19% firmer. $UUP closed 27.96 (+0.22%).
Crude fell on the day the Treasury Secretary unveiled a new sanctions programme aimed at Iran. WTI declined about 2.5% to roughly $84.89 and Brent about 2.5% to roughly $92.06; $USO closed 132.21 (-1.80%). Sanctions announcements that tighten financial channels without immediately removing barrels can lower the risk premium rather than raise it, and Monday priced the announcement that way. Natural gas moved the other direction, with $UNG closing 10.15 (+1.60%).
Gold rose while the dollar firmed. $GLD closed 426.69, up 0.79%, with spot gold at its highest level since mid-May. That pairing is the detail to hold: a gold advance driven by a weakening dollar is a currency trade, while a gold advance alongside a firmer dollar is a positioning trade in the metal itself. Bitcoin traded above $80,000 in the overnight session, an improvement on the weekend mark near $76,000.
6. Trade and Sanctions: Two Policy Inputs
Iran
The Treasury Secretary announced a sanctions programme aimed at isolating Iran from the global financial system, including measures against entities that assist Iranian money laundering, and signalled a further action against an unnamed financial institution before the end of the week. Oil closed lower on the announcement.
Canada
The bilateral dispute with Canada escalated, with a threatened tariff increase on Canadian automotive imports and a stated intention to match it. Mexico separately signalled optimism about its own negotiation after the Canadian talks stalled. Sector exposure, rather than index level, is where this shows up first.
Neither of these produced a clean index-wide move on Monday, which is worth registering as information in itself. When two live policy stories fail to dominate a session in which semiconductors fall more than 2%, the market is telling you which risk it considers scheduled and which it considers ambient.
7. Single-Stock Movers
| Ticker | Close | Day | What is documented |
|---|---|---|---|
| $LUCY | 1.12 | +63.77% | Strategic alliance with HTC Corporation and expansion into more than 150 U.S. big-box stores, both announced August 24. Volume approximately 195.4 million shares. |
| $BMEA | 1.59 | +16.06% | Completion of enrollment in a clinical study, announced August 24. |
| $CMPS | 14.20 | +6.53% | Continued August advance; no company release dated August 24 was located. |
| $TEM | 66.17 | -8.97% | An announced FDA clearance for an AI product on the same date did not hold the price. |
| $ASTS | 62.35 | -9.18% | No company-specific release dated August 24; the move tracked the broader risk tape. |
| $LUNR | 16.66 | -9.06% | No company-specific release dated August 24; gave back part of the multi-satellite award advance. |
| $UMAC | 24.57 | -10.43% | No company-specific release dated August 24; drone complex weakness. |
| $RGNX | 8.06 | -24.86% | FDA clinical hold on RGX-121, disclosed by company release and SEC filing. |
| $DFNS | 11.01 | -46.58% | No company release or SEC filing dated August 24 explaining the move was located. |
Two rows in that table carry a different weight from the others. $RGNX has a documented cause with a primary source attached. $DFNS does not, and the honest description is that a decline of that size on roughly 1.67 million shares has no located public explanation. A move without a document is a question, not a conclusion.
$MRNA closed 138.89, down 4.30%, and $MRK closed 150.66, down 1.24%, despite continued circulation of the August 19 Phase 3 result for intismeran autogene plus pembrolizumab in resected melanoma. A readout that is already five sessions old is priced; the coverage that follows it is not a second catalyst.
8. Fixed-Date Map
| Date | Event | Primary sensitivity |
|---|---|---|
| Tue, Aug 25 | FDA target action date for the Ziihera supplemental application in first-line HER2-positive gastroesophageal adenocarcinoma | $JAZZ 254.47, $ZYME 28.77 |
| Tue, Aug 25 | U.S. July new-home sales | Homebuilders, yields, cyclicals |
| Wed, Aug 26 — after close | NVIDIA fiscal second-quarter results; conference call 5:00 p.m. ET | $NVDA, semiconductors, AI infrastructure |
| Thu, Aug 27 | Gilead action date for once-daily bictegravir plus lenacapavir in HIV treatment | $GILD 146.74 |
| This week | Consumer confidence, GDP revision and the monthly inflation report | Treasuries, dollar, rate-sensitive equities |
| This week | Jackson Hole symposium; Fed Chair Kevin Warsh scheduled to speak | Treasuries, dollar, growth-duration assets |
The Jazz date is the nearest of these. The supplemental application covers Ziihera combinations in first-line HER2-positive gastroesophageal adenocarcinoma and is supported by the HERIZON-GEA-01 trial. Zymeworks is the originating partner, and partner reactions to a decision are frequently sharper in percentage terms than the reaction of the commercial owner, because the revenue base being repriced is smaller.
Bottom Line
Monday split the indices on sector composition rather than on macro news, and the split points at Wednesday. Semiconductors were de-risked broadly while financials, payments and utilities took the flow; gold rose against a firmer dollar; crude fell on a sanctions announcement. In small-cap biotech, two agency actions with primary documents attached moved two stocks in opposite directions, and one large decline in the defense complex has no located explanation at all. The distinction between a documented move and an undocumented one is the whole of the work this week.
Primary Sources and Method
Capricor PDUFA extension release · Capricor Form 8-K, August 24 · Regenxbio RGX-121 regulatory update · Regenxbio SEC exhibit · Jazz FDA acceptance and priority review · Gilead priority review release · NVIDIA reporting schedule · Merck and Moderna intismeran Phase 3 release · U.S. Treasury daily yield curve · U.S. Census release calendar · Federal Reserve August calendar.
Equity and ETF prices are last-sale closing-feed checks for Monday, August 24, 2026. Index levels are as reported for the same session. Treasury yield, dollar index, crude and bitcoin references are the levels cited by the sources listed above and can move materially after publication. Where a price move has no located primary document, that is stated in the text rather than filled with an inferred cause.
Live alerts: follow MerlinTrader on Telegram for verified headline updates.
For information and education only. Not investment advice. Verify prices, filings and event timing independently before trading.